Signifier® Medical Technologies Hosted a Global Webinar on: “Precision Medicine and Non-Invasive Therapies for Mild Obstructive Sleep Apnea”
LONDON, 3rd September 2020
Signifier Medical Technologies, an innovator in the sleep disordered breathing market, recently hosted a global webinar with leading world experts in the field of sleep disordered breathing (SDB).
The webinar was centred on “Precision Medicine and Non-Invasive Therapies for Mild Obstructive Sleep Apnea” and it was hosted by Prof. Dr. Adrian Williams (Professor of Sleep Medicine & Consultant Respiratory Physician, a founding member of the Sleep Section of the Royal Society of Medicine) and Prof. Dr. Atul Malhotra, (Research Chief in Pulmonary, Critical Care and Sleep Medicine at UC San Diego, USA).
Prof. Dr. Anshul Sama (Consultant ENT and Sleep Physician at Nottingham University Hospital, UK and inventor of the daytime intraoral neuromuscular electrical stimulation (NMES) technology1-2 for reduction of sleep disordered breathing) also participated in the webinar presenting the technology and the new therapy options provided by NMES.
The webinar shed light on the SDB space, current treatment modalities, and presented the mechanism of action and clinical data on the new NMES technology.
eXciteOSA® is a non-invasive daytime therapy for the tongue which delivers small contractions that improves muscle function and reduces the physiological collapse of the tongue during sleep. The device is a one size fits all and effective when used for 20 minutes a day for six weeks, with sustained improvement with minimal weekly maintenance.
Patients often find conventional night-time solutions for SDB ineffective or difficult to tolerate. With increasing public awareness of sleep related issues, and sleep therapy devices, it is increasingly likely that more patients will be consulting their healthcare professional on the therapy options available to them.
eXciteOSA® gives healthcare professionals and patients an effective therapy that is easy and convenient to use.
If you missed it live, visit www.exciteosa.com/past-webinars to view previous webinars on-demand and register for future webinars.
About Snoring and OSA
Nearly 1 billion adults aged 30 to 69 are estimated to have obstructive sleep apnea (OSA) globally. There is a strong, clinically proven link between obstructive sleep apnea and co-morbidities like diabetes, hypertension, and strokes. Mild OSA affects over 110 million people in the US and 100 million people in Europe.
Obstructive sleep apnea is marked by the recurring collapse of the upper airways during sleep. The most common symptoms are restless sleep, snoring, tiredness during the day, decreased intellectual alertness and personality alterations. Higher risks of cardiovascular diseases and increased mortality rates have been associated with OSA.
Standard therapy of all advanced levels of sleep apnea is with a continuous positive airway pressure (CPAP) device. Many patients find this therapy invasive, and the long-term compliance of CPAP therapy can be limited, so there is a demand for new and innovative approaches.
About Signifier Medical Technologies
Signifier Medical Technologies is a medical technology company focused on the development and commercialization of innovative and non-invasive solutions for patients with snoring and sleep disordered breathing conditions. Signifier’s proprietary therapy is the first and only daytime genioglossal (tongue) muscle-neurostimulation technology, with proven clinical data from prestigious and well-recognised universities and academic institutions, that provides a safe and effective therapy for patients.1-3
References
- Wessolleck E, Bernd E, Dockter S, et al. Intraoral electrical muscle stimulation in the treatment of snoring. Somnologie (Berl). 2018; 22 (Suppl 2): 47–52.
- Sama A, et al. Daytime Intraoral Neurostimulation with Snoozeal® for Treatment of Snoring and Mild Sleep Apnea. CHEST Annual Meeting Notes. 2018.
- Clinical study of 115 patients with snoring or mild OSA (Apnea- Hypopnea Index (AHI <15). Objective snoring and respiratory parameters were recorded with 2 consecutive WatchPat night sleep studies before and after the use of the device. An intra-oral tongue stimulator (Snoozeal®) device was used for 20mins, once a day for 6-week period
For media enquiries:
info@signifiermedical.com
+44 (0) 207 096 0586
